Skip to main content
Premium Trial:

Request an Annual Quote

Silence Therapeutics Issued Notice of Allowance for US Patent Application on Cancer Target

Premium

Silence Therapeutics said this week that it has received a notice of allowance from the US Patent and Trademark Office on a patent application directed to a cancer target and the use of RNAi molecules against it.

The target, PKN-3, is a protein kinase C-related molecule associated with the growth of cancer cells, as well as metastasis formation, and is the target for the company's phase I siRNA-based solid tumor drug Atu-027.

"The allowed subject matter is directed to, among other things, methods of treating cancer with small interfering RNA or antisense molecules that target the PKN-3 messenger RNA," the company said.

The Scan

New Study Highlights Role of Genetics in ADHD

Researchers report in Nature Genetics on differences in genetic architecture between ADHD affecting children versus ADHD that persists into adulthood or is diagnosed in adults.

Study Highlights Pitfall of Large Gene Panels in Clinical Genomic Analysis

An analysis in Genetics in Medicine finds that as gene panels get larger, there is an increased chance of uncovering benign candidate variants.

Single-Cell Atlas of Drosophila Embryogenesis

A new paper in Science presents a single-cell atlas of fruit fly embryonic development over time.

Phage Cocktail Holds Promise for IBD

Researchers uncovered a combination phage therapy that targets Klebsiella pneumonia strains among individuals experiencing inflammatory bowel disease flare ups, as they report in Cell.